EnteroTarget is a clinical stage company founded in 2018 based on an exclusive license to the patent “Rectal Insulin for treatment of inflammatory bowel disease”, which is granted in 15 European countries and in the US (pending in Canada). The patent is owned by University of Copenhagen and has two EnteroTarget founders among the inventors.
EnteroTarget’s product is named Enterocalm, which has topically acting insulin as the active pharmaceutical ingredient. The first version is EnteroCalm Enema which is to be followed by an orally administered version delivering topically acting insulin to the colon utilizing EnteroTarget’s proprietary capsule technology, the EnteroShuttle (patent pending).
We are partnering up with investors to bring the therapy to market with pouchitis and ulcerative colitis as the primary medical indications and with Crohn’s disease as a potential additional indication.
Currently, we are running phase 1 clinical trials and are preparing for a clinical phase 2 to meet the milestones in our ambitious business plan.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Ole Maaløes Vej 3, Copenhagen,capital Region 2200,denmark
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://enterotarget.com
- Keywords
- Biofynt.
- HQ
- Copenhagen, Capital Region
Enterotarget Questions
Enterotarget's website is http://enterotarget.com
Enterotarget's LinkedIn profile is https://dk.linkedin.com/company/enterotarget
Enterotarget has
8 employees.
View email and phone details for 8
employees at Enterotarget.
Enterotarget's industry is
Biotechnology Research
Enterotarget's top competitors are
Kiox Pharmaceuticals,
Biofynt,
Zuger Capital Ag,
Omnicin Therapeutics,
Culross Global Management Ltd,
Intubio,
Monta Biosciences,
Disperazol Pharma Aps,
Convatec,
Anres Clinical.
Enterotarget's categories are Biotechnology Research
Enterotarget's founding year is 2018
